Abhangi KV, Patel J (2022) Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson’s disease. Indian J Pharmacol 54:46–50. https://doi.org/10.4103/ijp.IJP_384_20

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ago Y, Asano S, Hashimoto H, Waschek JA (2021) Probing the VIPR2 microduplication linkage to schizophrenia in animal and cellular models. Front Neurosci 15:717490. https://doi.org/10.3389/fnins.2021.717490

Article  PubMed  PubMed Central  Google Scholar 

Ago Y, Van C, Condro MC, Hrncir H, Diep AL, Rajbhandari AK, Fanselow MS, Hashimoto H, MacKenzie-Graham AJ, Waschek JA (2023) Overexpression of VIPR2 in mice results in microencephaly with paradoxical increased white matter volume. Exp Neurol 362:114339. https://doi.org/10.1016/j.expneurol.2023.114339

Article  PubMed  CAS  Google Scholar 

Alhouayek M, Masquelier J, Muccioli GG (2018) Lysophosphatidylinositols, from Cell membrane constituents to GPR55 ligands. Trends Pharmacol Sci 39(6):586–604. https://doi.org/10.1016/j.tips.2018.02.011

Article  PubMed  CAS  Google Scholar 

Aljohani H, Alrubaish FS, Alghamdi WM, Al-Harbi F (2024) Safety of linagliptin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Ther Innov Regul Sci 58:622–633. https://doi.org/10.1007/s43441-024-00637-2

Article  PubMed  Google Scholar 

Amin FM, Schytz HW (2018) Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine. J Headache Pain 19(1):35. https://doi.org/10.1186/s10194-018-0861-3

Article  PubMed  PubMed Central  CAS  Google Scholar 

Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, van der Geest RJ, de Koning PJ, Larsson HB, Olesen J, Ashina M (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 32(2):140–149. https://doi.org/10.1177/0333102411431333

Article  PubMed  Google Scholar 

Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, de Koning PJ, Andersen MR, Larsson HB, Fahrenkrug J, Olesen J, Ashina M (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 137:779–794. https://doi.org/10.1093/brain/awt369

Article  PubMed  Google Scholar 

Apostol CR, Bernard K, Tanguturi P, Molnar G, Bartlett MJ, Szabò L, Liu C, Ortiz JB, Saber M, Giordano KR, Green TRF, Melvin J, Morrison HW, Madhavan L, Rowe RK, Streicher JM, Heien ML, Falk T, Polt R (2022) Design and synthesis of brain penetrant glycopeptide analogues of PACAP with neuroprotective potential for traumatic brain injury and parkinsonism. Front Drug Discov 1:818003. https://doi.org/10.3389/fddsv.2021.818003

Article  Google Scholar 

Arab HH, Eid AH, Alsufyani SE, Ashour AM, El-Sheikh AAK, Darwish HW, Georgy GS (2023) Neuroprotective impact of linagliptin against cadmium-induced cognitive impairment and neuropathological aberrations: targeting SIRT1/Nrf2 axis, apoptosis, and autophagy. Pharmaceuticals 16(8):1065. https://doi.org/10.3390/ph16081065

Article  PubMed  PubMed Central  CAS  Google Scholar 

Arimura A (1992) Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept 37:287–303. https://doi.org/10.1016/0167-0115(92)90621-z

Article  PubMed  CAS  Google Scholar 

Arimura A (2007) PACAP: the road to discovery. Peptides 28(9):1617–1619. https://doi.org/10.1016/j.peptides.2007.06.006

Article  PubMed  CAS  Google Scholar 

Arimura A, Shioda S (1995) Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol 16:1003. https://doi.org/10.1006/frne.1995.1003

Article  Google Scholar 

Arimura A, Somogyvári-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129:2787–2789. https://doi.org/10.1210/endo-129-5-2787

Article  PubMed  CAS  Google Scholar 

Ashina M (2020) Migraine. N Engl J Med 383:1866–1876. https://doi.org/10.1056/NEJMra1915327

Article  PubMed  CAS  Google Scholar 

Ashina M, Doležil D, Bonner JH, Zhou L, Klatt J, Picard H, Mikol DD (2021) A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 41(1):33–44. https://doi.org/10.1177/0333102420970889

Article  PubMed  Google Scholar 

Ashina H, Christensen RH, Hay DL, Pradhan AA, Hoffmann J, Reglodi D, Russo AF, Ashina M (2024) Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine. Nat Rev Neurol 20(11):660–670. https://doi.org/10.1038/s41582-024-01011-4

Article  PubMed  Google Scholar 

Banks WA, Uchida D, Arimura A, Somogyvári-Vigh A, Shioda S (1996) Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. Ann N Y Acad Sci 805:270–279. https://doi.org/10.1111/j.1749-6632.1996.tb17489.x

Article  PubMed  CAS  Google Scholar 

Banks WA, Kastin AJ, Arimura A (1998) Effect of spinal cord injury on the permeability of the blood-brain and blood-spinal cord barriers to the neurotropin PACAP. Exp Neurol 151(1):116–123. https://doi.org/10.1006/exnr.1998.6786

Article  PubMed  CAS  Google Scholar 

Banks WA (2016) Transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier: consequences for disease states and therapeutic effects. In: Reglodi D, Tamas A (eds) Pituitary Adenylate Cyclase Activating Polypeptide — PACAP, Current Topics in Neurotoxicity, Springer: Cham, Switzerland, Volume 11. https://doi.org/10.1007/978-3-319-35135-3_25

Barra T, Falanga A, Bellavita R, Laforgia V, Prisco M, Galdiero S, Valiante S (2022) a gH625-liposomes deliver PACAP through a dynamic in vitro model of the blood-brain barrier. Front Physiol 13:932099. https://doi.org/10.3389/fphys.2022.932099

Article  PubMed  PubMed Central  Google Scholar 

Barra T, Falanga A, Bellavita R, Pisano J, Laforgia V, Prisco M, Galdiero S, Valiante S (2022) b Neuroprotective effects of gH625-lipoPACAP in an in vitro fluid dynamic model of Parkinson’s disease. Biomedicines 10(10):2644. https://doi.org/10.3390/biomedicines10102644b

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bernard K, Dickson D, Anglin BL, Leandro Heien M, Polt R, Morrison HW, Falk T (2024) PACAP glycosides promote cell outgrowth in vitro and reduce infarct size after stroke in a preclinical model. Neurosci Lett 836:137883. https://doi.org/10.1016/j.neulet.2024.137883

Article  PubMed  CAS  Google Scholar 

Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, Olesen J (2007) The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 140:185–191

Article  PubMed  CAS  Google Scholar 

Borrajo ML, Alonso MJ (2022) Using nanotechnology to deliver biomolecules from nose to brain - peptides, proteins, monoclonal antibodies and RNA. Drug Deliv Transl Res 12(4):862–880. https://doi.org/10.1007/s13346-021-01086-2

Article  PubMed  CAS  Google Scholar 

Bourgault S, Vaudry D, Botia B, Couvineau A, Laburthe M, Vaudry H, Fournier A (2008) Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 29:919–932. https://doi.org/10.1016/j.peptides.2008.01.022

Article  PubMed  CAS  Google Scholar 

Bourgault S, Vaudry D, Dejda A, Doan ND, Vaudry H, Fournier A (2009a) Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide. Curr Med Chem 16:4462–4480. https://doi.org/10.2174/092986709789712899

Article  PubMed  CAS  Google Scholar 

Bourgault S, Vaudry D, Segalas-Milazzo I, Guilhaudis L, Couvineau A, Laburthe M, Vaudry H, Fournier A (2009) b Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. J Med Chem 52(10):3308–3316

Article  PubMed  CAS  Google Scholar 

Bourgault S, Chatenet D, Wurtz O, Doan ND, Leprince J, Vaudry H, Fournier A, Vaudry D (2011) Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug. Curr Pharm Des 17(10):1002–24.